{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:30:31Z","timestamp":1786595431016,"version":"build-2736575974"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100023065","name":"State of California","doi-asserted-by":"crossref","award":["SB840 and SB129 #44"],"award-info":[{"award-number":["SB840 and SB129 #44"]}],"id":[{"id":"10.13039\/100023065","id-type":"DOI","asserted-by":"crossref"}]},{"name":"KU Leuven Internal funds","award":["C14\/24\/125"],"award-info":[{"award-number":["C14\/24\/125"]}]},{"name":"Belgian Foundation against Cancer","award":["FAF 2020\/094"],"award-info":[{"award-number":["FAF 2020\/094"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01230-5","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:13:10Z","timestamp":1780917190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells"],"prefix":"10.1007","volume":"49","author":[{"given":"Eleonora","family":"Nigliato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Derua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Butyrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra P.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Guilmot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"De Gianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcveyda","family":"Dok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ohlmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Wadzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Nuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sablina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"1230_CR1","doi-asserted-by":"publisher","first-page":"1204722","DOI":"10.3389\/FONC.2023.1204722\/FULL","volume":"13","author":"RK Sahu","year":"2023","unstructured":"R.K. Sahu, S. Ruhi, A.K. Jeppu et al., Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front. Oncol. 13, 1204722 (2023). https:\/\/doi.org\/10.3389\/FONC.2023.1204722\/FULL","journal-title":"Front. Oncol."},{"issue":"13","key":"1230_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMRA1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"S.M. Janes, D. Alrifai, D.A. Fennell, Perspectives on the Treatment of Malignant Pleural Mesothelioma. N Engl. J. Med. 385(13), 1207\u20131218 (2021). https:\/\/doi.org\/10.1056\/NEJMRA1912719","journal-title":"N Engl. J. Med."},{"issue":"3","key":"1230_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/JCM14031004","volume":"14","author":"G Cardillo","year":"2025","unstructured":"G. Cardillo, D. Waller, S. Tenconi, Di V. Noia, S. Ricciardi, Malignant Pleural Mesothelioma: A 2025 Update. J. Clin. Med. 14(3), 1004 (2025). https:\/\/doi.org\/10.3390\/JCM14031004","journal-title":"J. Clin. Med."},{"key":"1230_CR4","doi-asserted-by":"publisher","first-page":"115716","DOI":"10.1016\/j.jenvman.2022.115716","volume":"319","author":"LP Thives","year":"2022","unstructured":"L.P. Thives, E. Ghisi, J.J. Thives J\u00fanior, A.S. Vieira, Is asbestos still a problem in the world? A current review. J. Environ. Manage. 319, 115716 (2022). https:\/\/doi.org\/10.1016\/j.jenvman.2022.115716","journal-title":"J. Environ. Manage."},{"issue":"4","key":"1230_CR5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/NG.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"R. Bueno, E.W. Stawiski, L.D. Goldstein et al., Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat. Genet. 48(4), 407\u2013416 (2016). https:\/\/doi.org\/10.1038\/NG.3520","journal-title":"Nat. Genet."},{"issue":"6","key":"1230_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/1878-0261.12651","volume":"14","author":"L Quetel","year":"2020","unstructured":"L. Quetel, C. Meiller, J.B. Assi\u00e9 et al., Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival. Mol. Oncol. 14(6), 1207\u20131223 (2020). https:\/\/doi.org\/10.1002\/1878-0261.12651","journal-title":"Mol. Oncol."},{"key":"1230_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.semcancer.2019.09.014","volume":"61","author":"TK Hinz","year":"2020","unstructured":"T.K. Hinz, L.E. Heasley, Translating mesothelioma molecular genomics and dependencies into precision oncology-based therapies. Semin Cancer Biol. 61, 11\u201322 (2020). https:\/\/doi.org\/10.1016\/j.semcancer.2019.09.014","journal-title":"Semin Cancer Biol."},{"issue":"8","key":"1230_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/NRC.2017.42","volume":"17","author":"TA Yap","year":"2017","unstructured":"T.A. Yap, J.G. Aerts, S. Popat, D.A. Fennell, Novel insights into mesothelioma biology and implications for therapy. Nat. Rev. Cancer. 17(8), 475\u2013488 (2017). https:\/\/doi.org\/10.1038\/NRC.2017.42","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"1230_CR9","doi-asserted-by":"publisher","first-page":"e13631","DOI":"10.15252\/EMMM.202013631","volume":"14","author":"A Marazioti","year":"2021","unstructured":"A. Marazioti, A.C. Krontira, S.J. Behrend et al., KRAS signaling in malignant pleural mesothelioma. EMBO Mol. Med. 14(2), e13631 (2021). https:\/\/doi.org\/10.15252\/EMMM.202013631","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"1230_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1200\/JCO.21.01567","volume":"40","author":"AS Tsao","year":"2022","unstructured":"A.S. Tsao, H.I. Pass, A. Rimner, A.S. Mansfield, New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J. Clin. Oncol. 40(6), 681\u2013692 (2022). https:\/\/doi.org\/10.1200\/JCO.21.01567","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"1230_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1136\/THORAXJNL-2020-216602","volume":"76","author":"M Shamseddin","year":"2021","unstructured":"M. Shamseddin, J. Obacz, M.J. Garnett, R.C. Rintoul, H.E. Francies, S.J. Marciniak, Use of preclinical models for malignant pleural mesothelioma. Thorax. 76(11), 1154\u20131162 (2021). https:\/\/doi.org\/10.1136\/THORAXJNL-2020-216602","journal-title":"Thorax"},{"issue":"11","key":"1230_CR12","doi-asserted-by":"publisher","first-page":"9165","DOI":"10.3390\/IJMS24119165","volume":"24","author":"F Borea","year":"2023","unstructured":"F. Borea, M.A. Franczak, M. Garcia et al., Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage? Int. J. Mol. Sci. 24(11), 9165 (2023). https:\/\/doi.org\/10.3390\/IJMS24119165","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"1230_CR13","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/S10552-017-0929-4","volume":"28","author":"ET Chang","year":"2017","unstructured":"E.T. Chang, E.C. Lau, F.S. Mowat, M.J. Teta, Therapeutic radiation for lymphoma and risk of second primary malignant mesothelioma. Cancer Causes Control. 28(9), 971\u2013979 (2017). https:\/\/doi.org\/10.1007\/S10552-017-0929-4","journal-title":"Cancer Causes Control"},{"issue":"6","key":"1230_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.5858\/ARPA.2017-0365-RA","volume":"142","author":"RL Attanoos","year":"2018","unstructured":"R.L. Attanoos, A. Churg, F. Galateau-Salle, A.R. Gibbs, V.L. Roggli, Malignant Mesothelioma and Its Non-Asbestos Causes. Arch. Pathol. Lab. Med. 142(6), 753\u2013760 (2018). https:\/\/doi.org\/10.5858\/ARPA.2017-0365-RA","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"1230_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2003.09.004","volume":"318","author":"G Barbanti-Brodano","year":"2004","unstructured":"G. Barbanti-Brodano, S. Sabbioni, F. Martini, M. Negrini, A. Corallini, M. Tognon, Simian virus 40 infection in humans and association with human diseases: Results and hypotheses. Virology. 318(1), 1\u20139 (2004). https:\/\/doi.org\/10.1016\/j.virol.2003.09.004","journal-title":"Virology"},{"key":"1230_CR16","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.21037\/tlcr.2020.02.03","volume":"9","author":"M Carbone","year":"2020","unstructured":"M. Carbone, A. Gazdar, J.S. Butel, SV40 and human mesothelioma. Transl Lung Cancer Res. 9, S47\u2013S59 (2020). https:\/\/doi.org\/10.21037\/tlcr.2020.02.03","journal-title":"Transl Lung Cancer Res."},{"issue":"4","key":"1230_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.semcancer.2009.03.002","volume":"19","author":"J Cheng","year":"2009","unstructured":"J. Cheng, J.A. DeCaprio, M.M. Fluck, B.S. Schaffhausen, Cellular transformation by Simian Virus 40 and Murine Polyoma Virus T antigens. Semin Cancer Biol. 19(4), 218\u2013228 (2009). https:\/\/doi.org\/10.1016\/j.semcancer.2009.03.002","journal-title":"Semin Cancer Biol."},{"key":"1230_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biocel.2017.10.002","volume":"96","author":"B Meeusen","year":"2018","unstructured":"B. Meeusen, V. Janssens, Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification. Int. J. Biochem. Cell. Biol. 96, 98\u2013134 (2018). https:\/\/doi.org\/10.1016\/j.biocel.2017.10.002","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"1","key":"1230_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.gde.2004.12.004","volume":"15","author":"V Janssens","year":"2005","unstructured":"V. Janssens, J. Goris, Van C. Hoof, PP2A: The expected tumor suppressor. Curr. Opin. Genet. Dev. 15(1), 34\u201341 (2005). https:\/\/doi.org\/10.1016\/j.gde.2004.12.004","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"Pt 3","key":"1230_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1042\/0264-6021:3530417","volume":"353","author":"V Janssens","year":"2001","unstructured":"V. Janssens, J. Goris, Protein phosphatase 2A: a highly regulated family of serine\/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 353(Pt 3), 417\u2013439 (2001). https:\/\/doi.org\/10.1042\/0264-6021:3530417","journal-title":"Biochem. J."},{"issue":"1","key":"1230_CR21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0092-8674(90)90726-U","volume":"60","author":"DC Pallas","year":"1990","unstructured":"D.C. Pallas, L.K. Shahrik, B.L. Martin et al., Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell. 60(1), 167\u2013176 (1990). https:\/\/doi.org\/10.1016\/0092-8674(90)90726-U","journal-title":"Cell"},{"issue":"4","key":"1230_CR22","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1128\/MCB.11.4.1988-1995.1991","volume":"11","author":"SI Yang","year":"1991","unstructured":"S.I. Yang, R.L. Lickteig, R. Estes, K. Rundell, G. Walter, M.C. Mumby, Control of protein phosphatase 2A by simian virus 40 small-t antigen. Mol. Cell. Biol. 11(4), 1988\u20131995 (1991). https:\/\/doi.org\/10.1128\/MCB.11.4.1988-1995.1991","journal-title":"Mol. Cell. Biol."},{"issue":"6","key":"1230_CR23","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/NSMB1254","volume":"14","author":"Y Chen","year":"2007","unstructured":"Y. Chen, Y. Xu, Q. Bao et al., Structural and biochemical insights into the regulation of protein phosphatase 2A by small t antigen of SV40. Nat. Struct. Mol. Biol. 14(6), 527\u2013534 (2007). https:\/\/doi.org\/10.1038\/NSMB1254","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"8","key":"1230_CR24","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1371\/JOURNAL.PBIO.0050202","volume":"5","author":"US Cho","year":"2007","unstructured":"U.S. Cho, S. Morrone, A.A. Sablina, J.D. Arroyo, W.C. Hahn, W. Xu, Structural basis of PP2A inhibition by small t antigen. PLoS Biol. 5(8), 1810\u20131819 (2007). https:\/\/doi.org\/10.1371\/JOURNAL.PBIO.0050202","journal-title":"PLoS Biol."},{"issue":"2","key":"1230_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1535-6108(04)00026-1","volume":"5","author":"W Chen","year":"2004","unstructured":"W. Chen, R. Possemato, K.T. Campbell, C.A. Plattner, D.C. Pallas, W.C. Hahn, Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell. 5(2), 127\u2013136 (2004). https:\/\/doi.org\/10.1016\/S1535-6108(04)00026-1","journal-title":"Cancer Cell."},{"issue":"24","key":"1230_CR26","doi-asserted-by":"publisher","first-page":"10474","DOI":"10.1158\/0008-5472.CAN-10-2855","volume":"70","author":"AA Sablina","year":"2010","unstructured":"A.A. Sablina, M. Hector, N. Colpaert, W.C. Hahn, Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 70(24), 10474\u201310484 (2010). https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2855","journal-title":"Cancer Res."},{"key":"1230_CR27","doi-asserted-by":"publisher","first-page":"e53003","DOI":"10.7554\/ELIFE.53003","volume":"9","author":"JW Kim","year":"2020","unstructured":"J.W. Kim, C. Berrios, M. Kim et al., STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells. Elife. 9, e53003 (2020). https:\/\/doi.org\/10.7554\/ELIFE.53003","journal-title":"Elife"},{"issue":"7","key":"1230_CR28","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1128\/MCB.22.7.2111-2123.2002","volume":"22","author":"WC Hahn","year":"2002","unstructured":"W.C. Hahn, S.K. Dessain, M.W. Brooks et al., Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol. Cell. Biol. 22(7), 2111\u20132123 (2002). https:\/\/doi.org\/10.1128\/MCB.22.7.2111-2123.2002","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"1230_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/S10555-008-9116-0","volume":"27","author":"AA Sablina","year":"2008","unstructured":"A.A. Sablina, W.C. Hahn, SV40 small T antigen and PP2A phosphatase in cell transformation. Cancer Metastasis Rev. 27(2), 137\u2013146 (2008). https:\/\/doi.org\/10.1007\/S10555-008-9116-0","journal-title":"Cancer Metastasis Rev."},{"issue":"2","key":"1230_CR30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/viro.2001.1204","volume":"290","author":"J Yu","year":"2001","unstructured":"J. Yu, A. Boyapati, K. Rundell, Critical role for SV40 small-t antigen in human cell transformation. Virology. 290(2), 192\u2013198 (2001). https:\/\/doi.org\/10.1006\/viro.2001.1204","journal-title":"Virology"},{"issue":"24","key":"1230_CR31","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.1158\/0008-5472.CAN-16-2911","volume":"77","author":"W Sents","year":"2017","unstructured":"W. Sents, B. Meeusen, P. Kalev et al., PP2A Inactivation Mediated by PPP2R4 Haploinsufficiency Promotes Cancer Development. Cancer Res. 77(24), 6825\u20136837 (2017). https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2911","journal-title":"Cancer Res."},{"issue":"4","key":"1230_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ONC.2017.350","volume":"37","author":"C Lambrecht","year":"2018","unstructured":"C. Lambrecht, L. Libbrecht, X. Sagaert et al., Loss of protein phosphatase 2A regulatory subunit B56\u03b4 promotes spontaneous tumorigenesis in vivo. Oncogene. 37(4), 544\u2013552 (2018). https:\/\/doi.org\/10.1038\/ONC.2017.350","journal-title":"Oncogene"},{"issue":"16","key":"1230_CR33","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.3390\/CANCERS15164193","volume":"15","author":"J Dom\u00e8nech Omella","year":"2023","unstructured":"J. Dom\u00e8nech Omella, E.E. Cortesi, I. Verbinnen et al., A Novel Mouse Model of Combined Hepatocellular-Cholangiocarcinoma Induced by Diethylnitrosamine and Loss of Ppp2r5d. Cancers (Basel). 15(16), 4193 (2023). https:\/\/doi.org\/10.3390\/CANCERS15164193","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1230_CR34","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1002\/JCP.29414","volume":"235","author":"R Pippa","year":"2020","unstructured":"R. Pippa, S. Boffo, M.D. Odero, A. Giordano, Data mining analysis of the PP2A cell cycle axis in mesothelioma patients. J. Cell. Physiol. 235(6), 5284\u20135292 (2020). https:\/\/doi.org\/10.1002\/JCP.29414","journal-title":"J. Cell. Physiol."},{"issue":"1","key":"1230_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/S12967-017-1158-Z","volume":"15","author":"A Szymiczek","year":"2017","unstructured":"A. Szymiczek, S. Pastorino, D. Larson et al., FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. J. Transl Med. 15(1), 58 (2017). https:\/\/doi.org\/10.1186\/S12967-017-1158-Z","journal-title":"J. Transl Med."},{"issue":"2","key":"1230_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1111\/J.1742-4658.2012.08579.X","volume":"280","author":"W Sents","year":"2013","unstructured":"W. Sents, E. Ivanova, C. Lambrecht, D. Haesen, V. Janssens, The biogenesis of active protein phosphatase 2A holoenzymes: a tightly regulated process creating phosphatase specificity. FEBS J. 280(2), 644\u2013661 (2013). https:\/\/doi.org\/10.1111\/J.1742-4658.2012.08579.X","journal-title":"FEBS J."},{"issue":"2","key":"1230_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/CR.2013.138","volume":"24","author":"F Guo","year":"2014","unstructured":"F. Guo, V. Stanevich, N. Wlodarchak et al., Structural basis of PP2A activation by PTPA, an ATP-dependent activation chaperone. Cell. Res. 24(2), 190\u2013203 (2014). https:\/\/doi.org\/10.1038\/CR.2013.138","journal-title":"Cell. Res."},{"key":"1230_CR38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2021.06.022","volume":"520","author":"B Meeusen","year":"2021","unstructured":"B. Meeusen, E.E. Cortesi, J. Dom\u00e8nech Omella, A. Sablina, J.J. Ventura, V. Janssens, PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition. Cancer Lett. 520, 57\u201367 (2021). https:\/\/doi.org\/10.1016\/j.canlet.2021.06.022","journal-title":"Cancer Lett."},{"issue":"269","key":"1230_CR39","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/SCISIGNAL.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"J. Gao, B.A. Aksoy, U. Dogrusoz et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6(269), pl1 (2013). https:\/\/doi.org\/10.1126\/SCISIGNAL.2004088","journal-title":"Sci. Signal."},{"issue":"5","key":"1230_CR40","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"E. Cerami, J. Gao, U. Dogrusoz et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2(5), 401\u2013404 (2012). https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0095","journal-title":"Cancer Discov"},{"issue":"23","key":"1230_CR41","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","volume":"83","author":"I de Bruijn","year":"2023","unstructured":"de I. Bruijn, R. Kundra, B. Mastrogiacomo et al., Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal. Cancer Res. 83(23), 3861\u20133867 (2023). https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0816","journal-title":"Cancer Res."},{"issue":"15","key":"1230_CR42","doi-asserted-by":"publisher","first-page":"13757","DOI":"10.18632\/ONCOTARGET.3765","volume":"6","author":"JJ Sacco","year":"2015","unstructured":"J.J. Sacco, J. Kenyani, Z. Butt et al., Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors. Oncotarget. 6(15), 13757\u201313771 (2015). https:\/\/doi.org\/10.18632\/ONCOTARGET.3765","journal-title":"Oncotarget"},{"issue":"3","key":"1230_CR43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/GLIA.440150310","volume":"15","author":"N Kley","year":"1995","unstructured":"N. Kley, J. Whaley, B.R. Seizinger, Neurofibromatosis type 2 and von Hippel-Lindau disease: from gene cloning to function. Glia. 15(3), 297\u2013307 (1995). https:\/\/doi.org\/10.1002\/GLIA.440150310","journal-title":"Glia"},{"issue":"27","key":"1230_CR44","doi-asserted-by":"publisher","first-page":"44232","DOI":"10.18632\/ONCOTARGET.17790","volume":"8","author":"L Urso","year":"2017","unstructured":"L. Urso, I. Cavallari, M. Silic-Benussi et al., Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists. Oncotarget. 8(27), 44232 (2017). https:\/\/doi.org\/10.18632\/ONCOTARGET.17790","journal-title":"Oncotarget"},{"issue":"4","key":"1230_CR45","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4161\/CC.27546","volume":"13","author":"D Di Marzo","year":"2014","unstructured":"Di D. Marzo, I.M. Forte, P. Indovina et al., Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma. Cell. Cycle. 13(4), 652\u2013665 (2014). https:\/\/doi.org\/10.4161\/CC.27546","journal-title":"Cell. Cycle"},{"issue":"1","key":"1230_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1074\/mcp.m500230-mcp200","volume":"5","author":"JC Silva","year":"2006","unstructured":"J.C. Silva, M.V. Gorenstein, G.Z. Li, J.P.C. Vissers, S.J. Geromanos, Absolute Quantification of Proteins by LCMSE. Mol. Cell. Proteom. 5(1), 144\u2013156 (2006). https:\/\/doi.org\/10.1074\/mcp.m500230-mcp200","journal-title":"Mol. Cell. Proteom."},{"issue":"8","key":"1230_CR47","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.3390\/CANCERS14081952","volume":"14","author":"LV Bownes","year":"2022","unstructured":"L.V. Bownes, R. Marayati, C.H. Quinn et al., Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma. Cancers (Basel). 14(8), 1952 (2022). https:\/\/doi.org\/10.3390\/CANCERS14081952","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1230_CR48","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/S41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"P. Bankhead, M.B. Loughrey, J.A. Fern\u00e1ndez et al., QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7(1), 16878 (2017). https:\/\/doi.org\/10.1038\/S41598-017-17204-5","journal-title":"Sci. Rep."},{"key":"1230_CR49","doi-asserted-by":"publisher","unstructured":"O. Burri, R. Dornier, N. loicsauteur, Chiaruttini, P. Sobolewski, T. Fehlmann, BIOP\/qupath-extension-cellpose: v0.12.0. https:\/\/doi.org\/10.5281\/ZENODO.18493147","DOI":"10.5281\/ZENODO.18493147"},{"key":"1230_CR50","doi-asserted-by":"publisher","unstructured":"M. Pachitariu, M. Rariden, C. Stringer, Cellpose-SAM: superhuman generalization for cellular segmentation. bioRxiv. Published online May 1, 2025:2025.04.28.651001. https:\/\/doi.org\/10.1101\/2025.04.28.651001","DOI":"10.1101\/2025.04.28.651001"},{"key":"1230_CR51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","volume":"60","author":"SM McGregor","year":"2017","unstructured":"S.M. McGregor, J. McElherne, A. Minor et al., BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma. Hum. Pathol. 60, 86\u201394 (2017). https:\/\/doi.org\/10.1016\/j.humpath.2016.09.026","journal-title":"Hum. Pathol."},{"issue":"2","key":"1230_CR52","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1006\/excr.2000.5144","volume":"264","author":"C Van Hoof","year":"2001","unstructured":"C. Van Hoof, V. Janssens, De I. Baere et al., The Saccharomyces cerevisiae phosphotyrosyl phosphatase activator proteins are required for a subset of the functions disrupted by protein phosphatase 2A mutations. Exp. Cell. Res. 264(2), 372\u2013387 (2001). https:\/\/doi.org\/10.1006\/excr.2000.5144","journal-title":"Exp. Cell. Res."},{"issue":"6","key":"1230_CR53","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/PL00008651","volume":"262","author":"B Rempola","year":"2000","unstructured":"B. Rempola, A. Kaniak, A. Migdalski, J. Rytka, P.P. Slonimski, Di J.P. Rago, Functional analysis of RRD1 (YIL153w) and RRD2 (YPL152w), which encode two putative activators of the phosphotyrosyl phosphatase activity of PP2A in Saccharomyces cerevisiae. Mol. Gen. Genet. 262(6), 1081\u20131092 (2000). https:\/\/doi.org\/10.1007\/PL00008651","journal-title":"Mol. Gen. Genet."},{"issue":"37","key":"1230_CR54","doi-asserted-by":"publisher","first-page":"26971","DOI":"10.1074\/jbc.M704059200","volume":"282","author":"S Longin","year":"2007","unstructured":"S. Longin, K. Zwaenepoel, J.V. Louis, S. Dilworth, J. Goris, V. Janssens, Selection of protein phosphatase 2A regulatory subunits is mediated by the C terminus of the catalytic subunit. J. Biol. Chem. 282(37), 26971\u201326980 (2007). https:\/\/doi.org\/10.1074\/jbc.M704059200","journal-title":"J. Biol. Chem."},{"issue":"2","key":"1230_CR55","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccr.2014.01.025","volume":"25","author":"J Cullis","year":"2014","unstructured":"J. Cullis, D. Meiri, M.J. Sandi et al., The RhoGEF GEF-H1 Is Required for Oncogenic Ras Signaling via KSR-1. Cancer Cell. 25(2), 181\u2013195 (2014). https:\/\/doi.org\/10.1016\/j.ccr.2014.01.025","journal-title":"Cancer Cell."},{"issue":"4","key":"1230_CR56","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1101\/GAD.962902","volume":"16","author":"F Roy","year":"2002","unstructured":"F. Roy, G. Laberge, M. Douziech, D. Ferland-McCollough, M. Therrien, KSR is a scaffold required for activation of the ERK\/MAPK module. Genes Dev. 16(4), 427 (2002). https:\/\/doi.org\/10.1101\/GAD.962902","journal-title":"Genes Dev."},{"issue":"16","key":"1230_CR57","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/S0960-9822(03)00535-9","volume":"13","author":"S Ory","year":"2003","unstructured":"S. Ory, M. Zhou, T.P. Conrads, T.D. Veenstra, D.K. Morrison, Protein Phosphatase 2A Positively Regulates Ras Signaling by Dephosphorylating KSR1 and Raf-1 on Critical 14-3-3 Binding Sites. Curr. Biol. 13(16), 1356\u20131364 (2003). https:\/\/doi.org\/10.1016\/S0960-9822(03)00535-9","journal-title":"Curr. Biol."},{"issue":"4","key":"1230_CR58","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/S41580-019-0110-X","volume":"20","author":"A Hafner","year":"2019","unstructured":"A. Hafner, M.L. Bulyk, A. Jambhekar, G. Lahav, The multiple mechanisms that regulate p53 activity and cell fate. Nat. Rev. Mol. Cell. Biol. 20(4), 199\u2013210 (2019). https:\/\/doi.org\/10.1038\/S41580-019-0110-X","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"3","key":"1230_CR59","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/BIOM10030420","volume":"10","author":"M Mijit","year":"2020","unstructured":"M. Mijit, V. Caracciolo, A. Melillo, F. Amicarelli, A. Giordano, Role of p53 in the Regulation of Cellular Senescence. Biomol. 2020. 10(3), 420 (2020). https:\/\/doi.org\/10.3390\/BIOM10030420","journal-title":"Biomol. 2020"},{"key":"1230_CR60","doi-asserted-by":"publisher","first-page":"751367","DOI":"10.3389\/FCELL.2022.751367","volume":"10","author":"RE C\u00e1ceres-Guti\u00e9rrez","year":"2022","unstructured":"R.E. C\u00e1ceres-Guti\u00e9rrez, Y. Alfaro-Mora, M.A. Andonegui, J. D\u00edaz-Ch\u00e1vez, L.A. Herrera, The Influence of Oncogenic RAS on Chemotherapy and Radiotherapy Resistance Through DNA Repair Pathways. Front. cell. Dev. Biol. 10, 751367 (2022). https:\/\/doi.org\/10.3389\/FCELL.2022.751367","journal-title":"Front. cell. Dev. Biol."},{"issue":"19","key":"1230_CR61","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1101\/GAD.12.19.3008","volume":"12","author":"AW Lin","year":"1998","unstructured":"A.W. Lin, M. Barradas, J.C. Stone, Van L. Aelst, M. Serrano, S.W. Lowe, Premature senescence involving p53 and p16 is activated in response to constitutive MEK\/MAPK mitogenic signaling. Genes Dev. 12(19), 3008\u20133019 (1998). https:\/\/doi.org\/10.1101\/GAD.12.19.3008","journal-title":"Genes Dev."},{"issue":"5","key":"1230_CR62","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","volume":"88","author":"M Serrano","year":"1997","unstructured":"M. Serrano, A.W. Lin, M.E. McCurrach, D. Beach, S.W. Lowe, Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16(INK4a). Cell. 88(5), 593\u2013602 (1997). https:\/\/doi.org\/10.1016\/S0092-8674(00)81902-9","journal-title":"Cell"},{"issue":"20","key":"1230_CR63","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1101\/GAD.17276711","volume":"25","author":"Y Chien","year":"2011","unstructured":"Y. Chien, C. Scuoppo, X. Wang et al., Control of the senescence-associated secretory phenotype by NF-\u03baB promotes senescence and enhances chemosensitivity. Genes Dev. 25(20), 2125\u20132136 (2011). https:\/\/doi.org\/10.1101\/GAD.17276711","journal-title":"Genes Dev."},{"issue":"4","key":"1230_CR64","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/J.CELLSIG.2011.12.006","volume":"24","author":"A Salminen","year":"2012","unstructured":"A. Salminen, A. Kauppinen, K. Kaarniranta, Emerging role of NF-\u03baB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell. Signal. 24(4), 835\u2013845 (2012). https:\/\/doi.org\/10.1016\/J.CELLSIG.2011.12.006","journal-title":"Cell. Signal."},{"key":"1230_CR65","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.biocel.2017.10.008","volume":"96","author":"CM O\u2019Connor","year":"2018","unstructured":"C.M. O\u2019Connor, A. Perl, D. Leonard, J. Sangodkar, G. Narla, Therapeutic targeting of PP2A. Int. J. Biochem. Cell. Biol. 96, 182\u2013193 (2018). https:\/\/doi.org\/10.1016\/j.biocel.2017.10.008","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"1230_CR66","doi-asserted-by":"publisher","first-page":"108834","DOI":"10.1016\/j.pharmthera.2025.108834","volume":"269","author":"DA Neale","year":"2025","unstructured":"D.A. Neale, J.C. Morris, N.M. Verrills, A.J. Ammit, Understanding the regulatory landscape of protein phosphatase 2A (PP2A): Pharmacological modulators and potential therapeutics. Pharmacol. Ther. 269, 108834 (2025). https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108834","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"1230_CR67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2007.06.034","volume":"130","author":"M Mumby","year":"2007","unstructured":"M. Mumby, PP2A: Unveiling a Reluctant Tumor Suppressor. Cell. 130(1), 21\u201324 (2007). https:\/\/doi.org\/10.1016\/j.cell.2007.06.034","journal-title":"Cell"},{"issue":"24","key":"1230_CR68","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1002\/1873-3468.12912","volume":"591","author":"Y Tsuchiya","year":"2017","unstructured":"Y. Tsuchiya, K. Osaki, M. Kanamoto et al., Distinct B subunits of PP2A regulate the NF-\u03baB signalling pathway through dephosphorylation of IKK\u03b2, I\u03baB\u03b1 and RelA. FEBS Lett. 591(24), 4083 (2017). https:\/\/doi.org\/10.1002\/1873-3468.12912","journal-title":"FEBS Lett."},{"issue":"12","key":"1230_CR69","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/onc.2011.339","volume":"31","author":"S Mannava","year":"2011","unstructured":"S. Mannava, A.R. Omilian, J.A. Wawrzyniak et al., PP2A-B56\u03b1 controls oncogene-induced senescence in normal and tumor human melanocytic cells. Oncogene. 31(12), 1484\u20131492 (2011). https:\/\/doi.org\/10.1038\/onc.2011.339","journal-title":"Oncogene"},{"issue":"14","key":"1230_CR70","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1158\/1078-0432","volume":"20","author":"A Laine","year":"2014","unstructured":"A. Laine, J. Westermarck, Molecular pathways: Harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. Clin. Cancer Res. 20(14), 3644\u20133650 (2014). https:\/\/doi.org\/10.1158\/1078-0432","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"1230_CR71","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/S00018-022-04275-5","volume":"79","author":"D Shang","year":"2022","unstructured":"D. Shang, T. Zhou, X. Zhuang, Y. Wu, H. Liu, Z. Tu, Molecular dissection on inhibition of Ras-induced cellular senescence by small t antigen of SV40. Cell. Mol. Life Sci. 79(5), 242 (2022). https:\/\/doi.org\/10.1007\/S00018-022-04275-5","journal-title":"Cell. Mol. Life Sci."},{"issue":"12","key":"1230_CR72","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1158\/1078-0432.CCR-07-4137","volume":"14","author":"W Li","year":"2008","unstructured":"W. Li, Z. Ge, C. Liu et al., CIP2A Is Overexpressed in Gastric Cancer and Its Depletion Leads to Impaired Clonogenicity, Senescence, or Differentiation of Tumor Cells. Clin. Cancer Res. 14(12), 3722\u20133728 (2008). https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-4137","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"1230_CR73","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/J.BBRC.2017.11.124","volume":"495","author":"X Yang","year":"2018","unstructured":"X. Yang, K. Qu, J. Tao et al., Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 495(2), 1807\u20131814 (2018). https:\/\/doi.org\/10.1016\/J.BBRC.2017.11.124","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"1230_CR74","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1158\/2159-8290","volume":"3","author":"A Laine","year":"2013","unstructured":"A. Laine, H. Sihto, C. Come et al., Cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov. 3(2), 182\u2013197 (2013). https:\/\/doi.org\/10.1158\/2159-8290","journal-title":"Cancer Discov"},{"key":"1230_CR75","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/s1383-5718(00)00043-7","volume":"468","author":"Z Ni","year":"2000","unstructured":"Z. Ni, Y. Liu, N. Keshava, G. Zhou, W.Z. Whong, T.M. Ong, Analysis of K-Ras and p53 Mutations in Mesotheliomas from Humans and Rats Exposed to Asbestos. Mutat. Res. 468, 87\u201392 (2000). https:\/\/doi.org\/10.1016\/s1383-5718(00)00043-7","journal-title":"Mutat. Res."},{"key":"1230_CR76","doi-asserted-by":"publisher","first-page":"111739","DOI":"10.1016\/J.CELLSIG.2025.111739","volume":"131","author":"T Nakada","year":"2025","unstructured":"T. Nakada, M. Koga, H. Takeuchi, K. Doi, H. Sugiyama, H. Sakurai, PP2A adapter protein IER5 induces dephosphorylation and degradation of MDM2, thereby stabilizing p53. Cell. Signal. 131, 111739 (2025). https:\/\/doi.org\/10.1016\/J.CELLSIG.2025.111739","journal-title":"Cell. Signal."},{"issue":"2","key":"1230_CR77","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/SJ.EMBOJ.7601519","volume":"26","author":"HH Li","year":"2007","unstructured":"H.H. Li, X. Cai, G.P. Shouse, L.G. Piluso, X. Liu, A specific PP2A regulatory subunit, B56\u03b3, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J. 26(2), 402 (2007). https:\/\/doi.org\/10.1038\/SJ.EMBOJ.7601519","journal-title":"EMBO J."},{"key":"1230_CR78","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S1097-2765(02)00504-X","volume":"9","author":"K Okamoto","year":"2002","unstructured":"K. Okamoto, H. Li, M.R. Jensen, G. Cyclin, Recruits PP2A to Dephosphorylate Mdm2 cyclin G can also increase the extent of TNF-induced. Mol. Cell. 9, 761\u2013771 (2002)","journal-title":"Mol. Cell."},{"issue":"5","key":"1230_CR79","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1165\/RCMB.2023-0105OC","volume":"69","author":"B Soto","year":"2023","unstructured":"B. Soto, H. Ahmed, M. Pillai et al., Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Emphysema. Am. J. Respir Cell. Mol. Biol. 69(5), 533 (2023). https:\/\/doi.org\/10.1165\/RCMB.2023-0105OC","journal-title":"Am. J. Respir Cell. Mol. Biol."},{"issue":"1","key":"1230_CR80","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"D. Hanahan, Hallmarks of Cancer: New Dimensions. Cancer Discov. 12(1), 31\u201346 (2022). https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059","journal-title":"Cancer Discov"},{"issue":"6","key":"1230_CR81","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/ncb1258","volume":"7","author":"JP MacKeigan","year":"2005","unstructured":"J.P. MacKeigan, L.O. Murphy, J. Blenis, Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell. Biol. 2005 76. 7(6), 591\u2013600 (2005). https:\/\/doi.org\/10.1038\/ncb1258","journal-title":"Nat. Cell. Biol. 2005 76"},{"key":"1230_CR82","doi-asserted-by":"publisher","first-page":"495645","DOI":"10.3389\/FONC.2020.00388\/FULL","volume":"10","author":"C Blanquart","year":"2020","unstructured":"C. Blanquart, M.C. Jaurand, D. Jean, The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models. Front. Oncol. 10, 495645 (2020). https:\/\/doi.org\/10.3389\/FONC.2020.00388\/FULL","journal-title":"Front. Oncol."}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01230-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01230-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01230-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T04:22:00Z","timestamp":1786594920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01230-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":82,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1230"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01230-5","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics declaration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest. B.E.W. is a co-founder of Turkey Creek Biotechnology (TCB); TCB was not involved in this work. Mount Sinai School of Medicine has filed patents on ATUX-792 on behalf of M.O.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"110"}}